Barclays PLC Sells 3,263 Shares of VanEck Pharmaceutical ETF (NASDAQ:PPH)

Barclays PLC lowered its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 73.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,173 shares of the company’s stock after selling 3,263 shares during the period. Barclays PLC’s holdings in VanEck Pharmaceutical ETF were worth $112,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Townsquare Capital LLC grew its holdings in shares of VanEck Pharmaceutical ETF by 3.8% in the third quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after acquiring an additional 130 shares during the period. FMR LLC grew its holdings in shares of VanEck Pharmaceutical ETF by 12.5% in the third quarter. FMR LLC now owns 1,905 shares of the company’s stock worth $181,000 after acquiring an additional 212 shares during the period. Beck Capital Management LLC grew its holdings in shares of VanEck Pharmaceutical ETF by 1.5% in the second quarter. Beck Capital Management LLC now owns 21,274 shares of the company’s stock worth $1,946,000 after acquiring an additional 317 shares during the period. Assetmark Inc. grew its holdings in shares of VanEck Pharmaceutical ETF by 5.8% in the third quarter. Assetmark Inc. now owns 6,491 shares of the company’s stock worth $617,000 after acquiring an additional 354 shares during the period. Finally, Harbour Investments Inc. grew its holdings in shares of VanEck Pharmaceutical ETF by 16.6% in the third quarter. Harbour Investments Inc. now owns 3,425 shares of the company’s stock worth $325,000 after acquiring an additional 488 shares during the period.

VanEck Pharmaceutical ETF Price Performance

Shares of PPH opened at $87.07 on Thursday. VanEck Pharmaceutical ETF has a one year low of $83.60 and a one year high of $99.51. The firm has a market capitalization of $599.91 million, a P/E ratio of 21.04 and a beta of 0.72. The business has a fifty day moving average of $88.54 and a 200 day moving average of $92.42.

VanEck Pharmaceutical ETF Increases Dividend

The business also recently announced a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were given a dividend of $0.411 per share. The ex-dividend date was Friday, December 27th. This is an increase from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.